Your browser doesn't support javascript.
loading
A diabetes registrar assisted workflow intervention in general practice for systematic initiation of cardiorenal medications for patients with type 2 diabetes and albuminuria in Aotearoa New Zealand.
Niyagama, Anjana; Moffitt, Allan; Patel, Mahesh; Strickland, Minnie; Aprea, Sara; Chepulis, Lynne; Paul, Ryan; Schmiedel, Ole; Murphy, Rinki.
Affiliation
  • Niyagama A; Department of Diabetes, Te Toka Tumai, Te Whatu Ora - Health New Zealand, New Zealand.
  • Moffitt A; ProCare Health Limited, Tamaki Makaurau Auckland, New Zealand.
  • Patel M; Total Health Care, Tamaki Makaurau Auckland, New Zealand.
  • Strickland M; Etu Pasifika Limited, Tamaki Makaurau Auckland, New Zealand.
  • Aprea S; ProCare Health Limited, Tamaki Makaurau Auckland, New Zealand.
  • Chepulis L; Medical Research Centre, Te Huataki Waiora School of Health, University of Waikato, Hamilton, New Zealand.
  • Paul R; Medical Research Centre, Te Huataki Waiora School of Health, University of Waikato, Hamilton, New Zealand; Te Whatu Ora - Health New Zealand Waikato, Hamilton, New Zealand.
  • Schmiedel O; Department of Diabetes, Te Toka Tumai, Te Whatu Ora - Health New Zealand, New Zealand.
  • Murphy R; Department of Diabetes, Te Toka Tumai, Te Whatu Ora - Health New Zealand, New Zealand; Faculty of Medical and Health Sciences, The University of Auckland, Tamaki Makaurau Auckland, New Zealand.
N Z Med J ; 136(1587): 52-64, 2023 Dec 15.
Article in En | MEDLINE | ID: mdl-38096435
AIMS: To evaluate whether a weekly diabetes registrar clinic and case discussions conducted over 12 weeks in primary care improves guideline management of type 2 diabetes (T2D). METHODS: A registrar-led diabetes clinic was incorporated into two primary care practices in Tamaki Makaurau Auckland for 3 months. Patients with T2D and albuminuria appearing on practice dashboards as not prescribed angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB), or sodium-glucose cotransporter-2 inhibitor/glucagon-like peptide-1 receptor agonist (SGLT2i/GLP1RA) were booked into these clinics. Opportunistic education sessions were provided by the diabetes registrar and prescribers were surveyed to understand the challenges in management of T2D. RESULTS: Of 125 patients booked, 80 attended the registrar clinic. Of these, 68% were clinically suitable for SGLT2i/GLP1RA and 8% for ACEi/ARB. SGLT2i/GLP1RA were initiated in 92% and ACEi/ARB in 89% of eligible patients. Two patients had contraindications for SGLT2i/GLP1RA, and one patient declined both. Additional cardiorenal medications were initiated in 16% of patients. Survey responses of 12 prescribers indicated acute illness takes priority over diabetes management, and lack of time and knowledge are main barriers to optimising diabetes care. CONCLUSIONS: A visiting diabetes registrar intervention was successful in initiating guideline medications for T2D in primary care. It remains to be evaluated whether this leads to practice-wide improvements in prescribing gaps in the short or longer term.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / General Practice / Sodium-Glucose Transporter 2 Inhibitors Limits: Humans Country/Region as subject: Oceania Language: En Journal: N Z Med J Year: 2023 Document type: Article Affiliation country: Country of publication:
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / General Practice / Sodium-Glucose Transporter 2 Inhibitors Limits: Humans Country/Region as subject: Oceania Language: En Journal: N Z Med J Year: 2023 Document type: Article Affiliation country: Country of publication: